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Abstract
Aim – the search for biologically active compounds with diuretic and hypoglycemic action among 7-substituted of 
3-benzyl-8-propylxanthines, which can be used for the treatment of pathologies of “metabolic syndrome”.
Materials and methods. 30 new chemical compounds among derivatives of 7-substituted of 3-benzyl-8-propylxanthines by 
PASS prediction filter were chosen for diuretic and hypoglycemic activity researches. Diuretic, hypoglycemic activity and for the most 
active compounds – the acute toxicity were studied in vivo. The molecular docking, which is based on EADock DSS mechanism of the 
modulation displayed the interaction between some of functional groups inside discovered xanthine ligands and known receptors and 
enzymes presented in Ligand-protein Database of Swiss Institute of Bioinformatics. 
Results. It has been shown that synthesized compounds displayed strong diuretic and medium hypoglycemic activities. The 
molecular docking modulation (SwissDock) of interaction of xanthine derivatives hits with proposed receptors and enzymes revealed 
prospective of using 7-substituted of 3-benzyl-8-propylxanthines as potential drugs for treatment of metabolic syndrome pathologies.
Conclusion. The diuretic activity of the new 23 compounds of 7-substituted of 3-benzyl-8-propylxanthines and hypoglycemic 
activity of the new 7 derivatives of 7-substituted of 3-benzyl-8-propylxanthines was studied. Results of performed investigation illus-
trate that 7-substituted of 3-benzyl-8-propylxanthines demonstrate biological activity comparable to standard drugs. We also proposed 
probable molecular targets for the most active compounds by molecular docking method. It was shown that derivatives of 7-substituted 
of 3-benzyl-8-propylxanthines can be used for metabolic syndrome disorders prevention.
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1. Introduction
The prevalence of the metabolic syndrome (MS) is the actual problem among adult pop-
ulation of the developed countries [1]. In general MS is associated with increasing of everyday 
calories intake, sedentary lifestyle, which is based on the improvement access to quality food 
and the progress of the technology in which human is engaged on intelligent levels of manage-
ment [2].
Unfortunately, according to the WHO data [3] of post-industrial countries the frequency of 
MS is 10–20 % among 30 years and older population, in the USA – 34 % (44 % for those who are 
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older 50 years). In addition, survey of American Diabetes Association shows that current syndrome 
demonstrates impetuous growth of appearance between teenagers and young people [4].
Nowadays, MS includes so-called “deadly” quartet – arterial hypertension, diabetes melli-
tus type 2, dyslipidemia and alimentary obesity [5].
An unpleasant feature of the combination of these diseases is that each of them get worse the 
progression of the other, that is, a vicious circle is formed.
Therefore, the search for drugs that would affect individual links of MS, improving carbo-
hydrate and lipid metabolism, reducing arterial pressure can be useful in treating this “disease of 
civilization”.
The attention of scientists who are searching for biologically active substances, is attracted 
by the natural nitrogen-containing heterocyclic systems [6], and the xanthine derivatives [7, 8] oc-
cupy a special place in this, among which, as well as several effective non-toxic drugs.
Aim of the research. Considering the above objective, the purposeful search for biologically 
active compounds among 7-substituted of 3-benzyl-8-propylxanthines became an aim of our work.
2. Materials and methods
Derivatives of 7-substituted of 3-benzyl-8-propylxanthines were previously synthesized by 
our scientific team [9, 10]. 
The research was coordinated with the internal commission of Zaporizhzhia State Medical 
University on bioethics (ZSMU Act No. 1 of 10.01.2019).
Experiments with animals were performed in the Scientific medical-laboratory center of the 
Zaporizhzhia State Medical University, certified by the SEC of the Ministry of Health of Ukraine 
(certificate No. 039/14). During the experiment, the animals were kept in the vivarium at a tempera-
ture of 20–22 °C and 50 % humidity in a well-ventilated room, under the conditions of natural dark/
light cycle with free access to food and water.
All manipulations with animals were performed out in accordance with the requirements 
of GLP, the recommendations of “European Union Directive 2010/63 / EU on the protection of 
animals used for scientific purposes” [11].
Animals were achieved from nursery of State Institute of Pharmacology and Toxicology of 
National Medical Academy of Ukraine. 
The study of diuretic activity was performed on nonlinear rats weighing 135-288 g using the 
Berkhin method [12]. For the observation of diuretic activity was used 7 rats in each group. In the 
study of water diuresis, rats were kept on a constant diet with free access to water. To the water load 
animals were kept for two hours without food and water. Subsequently, the animals were injected 
into the stomach with the help of a probe of the test substance in the form of aqueous suspension 
at the same time as an aqueous loading in the amount of 3 ml per 100 g body weight of the animal. 
Urine was collected every hour for 4 hours. Hydrochlorothiazide was used as reference drug.
Hypoglycemic activity (in vivo) was modelled by an oral glucose tolerance test [13], which 
was simulated by a load of animals at a dose of 2 g/kg body weight. The study used nonlinear 
white rats weighing 128–163 g, divided into 10 groups of 7 rats in each: 1 – intact; 2 – control of 
glycaemia without treatment; 3–9 – with the use of the studied xanthine derivatives; 10 – with 
glibenclamide therapy (5 mg/kg).The blood sample was taken from the femoral vein in 30 minutes. 
The glucose level was measured by the glucose oxidase method.
Molecular docking experiments were performed at the SwissDock web server (http://www.
swissdock.ch, this server is free for academic use) [14, 15]. 
The results of the research were processed by modern methods of the analysis on personal 
computer with the use of a statistical package Statistica® for Windows 6.0 license program (Stat-
Soft Inc., License No. AXXR712 D833214FAN5). The normality of distribution of quantitative 
signs was analyzed by Shapiro–Wilk’s test. The parameters had normal distribution. The compari-
son of indicators in groups was carried out with the use of Student’s test. The difference on р<0.05 
was considered statistically significant. All tests were bilateral. For definition of reliable distinc-
tions between quality indicators the non-parametric statistical criteria were used (the analysis of 
tables – criterion χ2).
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4. Results
For the enzyme DPP-4 [16], we have calculated the interaction with phenylthiosemicarbazone 
of 3-benzyl-8-propylxanthynyl-7 acetic acid. The classic inhibition of this enzyme is the covalent 
interaction with serine 630 (the major nucleophile involved in the hydrolase reaction). Molecular 
docking displayed possible interactions to form a hydrogen bond with threonine 304 and hydrophobic 
interaction with phenylalanine 208, which prevents suitable substrate to the active site nucleophile.
Molecular docking revealed the formation of three hydrophobic bindings between phenylth-
iosemicarbazone of 3-benzyl-8-propylxanthynyl-7 acetic acid and glycine 47, isoleucine 46 and 
218, which correlates with the inhibition data of enzyme 11β-hydroxysteroid dehydrogenase type 
1 (HSD 11B1) [17].
Also, by molecular docking [18], we have found possible agonistic activity through forming 
hydrogen bonds between phenylthiosemicarbazone of 3-benzyl-8-propylxanthynyl-7 acetic acid 
and the receptor peroxisomal proliferative activating receptor gamma (γ-PPAR).
We achieved the result of molecular docking, which indicate the presence of interactions 
between hydrazide 3-benzyl-8-propylxanthinyl-7 acetic acid and phenylalanine 1276, which blocks 
interaction of A1-receptor [19] with targeted mediator – adenosine.
Results of diuretic and hypoglycemic activities is presented in Tables 1, 2.
Table 1
Diuretic activity of derivatives of 3-benzyl-8-propylxanthinyl-7 acetic acid 
Compound Х* 120 min,
∆ %
240 min,
∆ %
1 2 3 4
Hydrochlorothiazide  78.79 73.10
Е-71 –NH–N=CH–C
6
H5 14.42 42.62
Е-104 –NH–N=CH–p–C
6
H4Br 70.19 82.51
Е-79 –NH–N=CH–p–C
6
H4F 95.19 81.42
Е63- –NH–N=CH–p–C
6
H4–N(CH3)2 –20.19 –24.04
Е-78 –NH–N=CH–p–C
6
H4NO2 –9.62 13.66
Е-121 –NH–N=CH–m–C
6
H4СН3 2.97 132.57
Е-77 –NH–N=CH–m–C
6
H4NO2 29.70 26.29
Е-122 –NH–N=CH–о–C
6
H4–OEt 3.96 –5.14
Е-125 –NH–N=CH–о–C
6
H4NO2 60.40 95.43
Е-127 –NH–N=CH–CH=СH–СH3 37.62 27.43
Е-126 –NH–N=CH–CH=СH–С
6
H5 –14.85 13.14
Е-129 HN N
N
N
Cl
81.40 67.20
Е-130 H
N N
N
N
Cl
2.33 32.80
Е-91
H
N N
NH
O
66.28 34.95
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Note: * – 
HN
N N
N
O
O
X
O
Table 2
Hypoglycemic activity of derivatives of hydrazide of 3-benzyl-8-propylxanthinyl-7 acetic acid
Compound X* Glucose level, %
1 2 3
Control  100
Intact  –35.76
Glibenclamide  –45.66
Е-168
NH2
S
–0.91
Е-165 N
H
S
–1.24
Е-64
N
H
S –50.29
Е-135
S
N
O
Phe
–11.23
1 2 3 4
Е-153 H
N N
H3C
Cl
86.05 6.45
Е-154 H
N N
H3C
O
67.44 39.78
E-61 –NH–NH2 88.46 144.26
E-166 –O–n–Hex 62.63 68.28
E-167 –O–n–Hep 5.05 121.38
E-147 –p–C
6
H4–OCH3 39.39 133.10
E-174 –O–n–But 62.63 108.97
E-58 –O–n–Pr 53.54 114.48
E-62 –C
6
H5 8.08 66.21
Continuation of Table 1
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Note: *  – 
HN
N N
N
O
O
H
N
O
NH
X
As it shown in the Table 1, most of the tested compounds demonstrated diuretic activity. Ex-
ception – compound E-63 with antidiuretic activity in period 2 and 4 hours, compounds E-78 and 
E-126 with antidiuretic manifestation in short period (2 h) and weak diuretic activity after 4 h. The 
most active compound – E-61 (hydrazide of 3-benzyl-8-propylxanthinyl-7 acetic acid) displayed 
activity in 1.97 time bigger than reference drug hydrochlorothiazide (144.26 % in comparison with 
73.10 %).
Table 2 data illustrate that four of investigated compounds have hypoglycemic activity, 
but only E-64 exceeds the value of reference drug – glibenclamide (decreasing of glucose level on 
50.29 %).
5. Discussion
The most promising mechanisms of the hypoglycemic activity is the increasing of insulin 
secretion. It is known that inhibition of the enzyme dipeptidyl peptidase 4 (DPP 4) [20] leads to the 
accumulation of incretins – Glucagon-like peptide-1 (GLP-1) [21] and glucose-dependent insulino-
tropic peptide (GIP) [22], that stimulate insulin release and inhibit glucagon secretion. In difference 
of the most commonly used drugs, such as insulin and sulfonylurea, GLP-1 therapy is associated 
with both weight loss and is accompanied by a lower risk of pathological hypoglycaemia, important 
manifestations for patients with type 2 diabetes mellitus.
In addition, it is known that cortisol is a powerful contrinsular hormone [23]. Accumulation 
of this glucocorticoid leads to an increase in gluconeogenesis, suppression of glucose transpor-
tation to cells, desensitization of insulin receptors, the stimulation of anabolic pathways for the 
deposition of energy macromolecules and increased blood pressure. In the biosynthesis of this cor-
ticosteroid hormone the crucial role is played by the enzyme – 11β-hydroxysteroid dehydrogenase 
type 1 (HSD 11B1), inhibition of which can improve the stresses caused by this hormone.
Peroxisomal proliferative activating receptor gamma (γ-PPAR) [24] is a transcriptional fac-
tor that belongs to the superfamily of nuclear receptors, is involved in the absorption and storage of 
1 2 4
E-178
N
S
2.31
E-179 N
S
CH3
O
OH
O
6.03
E-180
H
N
CH3
S
0.33
Continuation of Table 2
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fatty acids, glucose homeostasis, and has an anti-inflammatory effect. Synthetic g-PPAR agonists 
can be widely used in the treatment of dyslipidemia, hyperglycemia and their combination.
According to numerous investigations [25], diuretic drugs play an important role for the 
treatment of arterial hypertension. Many natural and synthetic xanthines are characterized by di-
uretic action, which, corresponding to the literature, is realized, due to the blocking of A1 adenos-
ine receptors [26].
Up-to-date commonly used in silico methods, regrettably, have certain restrictions due 
imperfect prediction algorithms. Despite to some raw estimation of calculated results, presented 
investigations may been used as a possible way for the future researchesfor the prediction of the 
biological activity among substituted xanthines.
6. Conclusion
The diuretic activity of the new 23 compounds of 7-substituted of 3-benzyl-8-propylxan-
thines and hypoglycemic activity of the new 7 derivatives of 7-substituted of 3-benzyl-8-propylx-
anthines was studied. Results of performed investigation illustrate that 7-substituted of 3-benzyl- 
8-propylxanthines demonstrate biological activity comparable to standard drugs. We also proposed 
probable molecular targets for the most active compounds by molecular docking method. It was 
shown that derivatives of 7-substituted of 3-benzyl-8-propylxanthines can be used for metabolic 
syndrome disorders prevention.
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